期刊文献+

一例两种新的ADAMTS13基因突变导致的遗传性血栓性血小板减少性紫癜 被引量:11

Identification of two novel mutations in ADAMTS13 gene in a patient with hereditary thrombotic thrombocytopenic purpura
原文传递
导出
摘要 目的对1例高度可疑的遗传性血栓性血小板减少性紫癜(TTP)患者的vWF裂解蛋白酶(ADAMTS13,vWF-cp)基因突变进行检测,以明确诊断并制定相应的治疗方案。方法用残余胶原结合实验(residual-collagen binding assay)动态检测1例TTP患者ADAMTS13的活性和抑制物水平。用PCR方法扩增ADAMTS13的29个外显子及外显子邻近处的内含子,并直接测序检测突变。对其亲属的基因组DNA在患者突变区域扩增并测序。结果患者ADAMTS13活性降低,未发现抑制物存在。测序显示患者的ADAMTS13的凝血酶敏感蛋白1(TSP1)基序重复区第21外显子碱基2708处和25号外显子碱基3283处出现C→T的错义突变(均为纯合子),分别导致该碱基参与编码的丝氨酸密码子(TCG)变为亮氨酸密码子(TTG)(S903L),精氨酸密码子(CGG)变为色氨酸密码子(TGG)(R1095W)。患者父母上述突变位置处的基因均呈杂合状态,其兄的该段碱基序列正常,并且在采集的25位家族成员中共发现11名上述突变位点的正常携带者。结论该患者是由于ADAMTS13基因纯合子错义突变导致翻译发生错误所致的遗传性TTP。 Objective To investigate the gene mutations of ADAMTS13 in a highly suspected hereditary thromhoeytopenie purpura (TTP) patient, and then make a progressive diagnosis and adjust the plan of therapy. Methods ADAMTS13 activity and inhibitor were determined by residuat-collagen binding assay during several episodes. Genomic DNA extracted from the prohand's peripheral blood was used for amplification of 29 exons anti exon/intron boundaries of ADAMTS13 by PCR. The PCR products were screened hy direct sequencing and the gene alterations were further confirmed hy direet sequeneing in her family memhers. Result The activity of the proband's ADAMTS13 was significantly reduced while no inhibitor was found. Two novel missense mutations were found in the TSP1 repeated motif domain of ADAMTS13. In both mutations, thymine substituted for eytidine, resulting in the substitution of leueine for serine in nt 2708, exon21 (codon S903L), and tryptophan for arginine in nt 3283, exon 25 (eodon R1095W). These two mutations were revealed as each heterozygote in the prohand's parents. Conclusion The deficiency of ADAMTS13 caused by two homozygote missense mutations might be responsible for episode of this TTP patient.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2005年第9期521-524,共4页 Chinese Journal of Hematology
基金 国家自然科学基金资助项目(30470732)
  • 相关文献

参考文献1

二级参考文献10

  • 1OleksowiczL,BhagwatiN,DeLeonFernandez,etal.DificientactivityofvonWillebrand’sfactor cleavingproteasein patientswithdisseminatedmalignancies[].Cancer Research.1999
  • 2StudtJD,BhmM,BuddeU ,etal.MeasurementofvonWillebrandfactor cleavingprotease (ADAMTS13)activityin plasma:amulticentercomparisonofdifferentassaymethods[].JThrombHaemost.2003
  • 3Furlan M,Robles R,Galbusera M,et al.von Willebrand factorcleaving protease in thrombotic thrombocyto-penic purpura and the hemolytic-uremic syndrome[].The New England Journal of Medicine.1998
  • 4Tsai HM,Lian EC.Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura[].The New England Journal of Medicine.1998
  • 5Zheng X,Chung D,Takayama T K,et al.Structure of von Willebrand factor-Cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura[].Journal of Biological Chemistry.2001
  • 6Moake JL.Thrombotic microangiopathies[].The New England Journal of Medicine.2002
  • 7Mannucci PM,Karimi M,Mosalaei A,et al.Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS13 (von Willebrand factor cleaving protease)[].Haematologica.2003
  • 8Xi X,Ruan C,Li P, et al.Use of monoclonal antibodies in enzyme-linked immunoassay for von Willebrand factor[].Chin J Med Lab Sci.1988
  • 9Tsai HM.High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura[].American Journal of Hematology.2000
  • 10Rock G,Porta C,Bobbio-Pallavicini E,et al.Thrombotic thrombocytopenic purpura treatment in year 2000[].Haematologica.2000

共引文献14

同被引文献79

引证文献11

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部